ReviewCurrent oncology reports2022
Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications.
Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Significant association between high neutrophil-lymphocyte ratio and poor prognosis in patients with hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management.World journal of hepatology · 2025Review
- International perspectives on LI-RADS.Abdominal radiology (New York) · 2025Review
- HN1-mediated activation of lipogenesis through Akt-SREBP signaling promotes hepatocellular carcinoma cell proliferation and metastasis.Cancer gene therapy · 2024Article
- Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.Journal of liver cancer · 2024Article
- MAFLD: an optimal framework for understanding liver cancer phenotypes.Journal of gastroenterology · 2023Review
- Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma.Hepatology international · 2023Article
- Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Identification of a novel circRNA-miRNA-mRNA regulatory axis in hepatocellular carcinoma based on bioinformatics analysis.Scientific reports · 2023Article
- Association between smoking and non-alcoholic fatty liver disease in Southeast Asia.Frontiers in public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewLiver cancer is a major health burden globally with high rates in the Far East and Southeast Asia. Hepatitis B virus and hepatitis C virus remain the major causes of hepatocellular carcinoma (HCC) worldwide; however, the epidemiology is changing. Here, we review the changing epidemiological changes among Far East and Southeast Asians and among Asian Americans in the USA. RECENT
findingsHBV- and HCV-induced HCC is anticipated to decline in incidence. In contrast, nonalcoholic fatty liver disease-induced HCC will outrank viral hepatitis in the next decade. Alcoholic liver disease will remain a persistent risk factor for HCC. These epidemiological shifts might have implications for the care of patients with HCC as described in this review. Societal changes are impacting the global incidence of HCC and will likely also impact the care of patients with this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.